Neurocrine biosciences reports positive phase 2 data for nbi-1117568 in adults with schizophrenia

The once-daily 20 mg dose met the primary endpoint, demonstrating a statistically significant 7.5-point improvement (p=0.011, 0.61 effect size) in the panss total score compared to placebo at week 6 with an 18.2-point panss total score improvement from baseline the once-daily 20 mg dose met additional endpoints, demonstrating statistically significant improvements in clinical global impression of severity scale and marder factor score positive symptom change and negative symptom change nbi-'568 was generally safe and well tolerated at all doses studied the once-daily 20 mg dose efficacy, safety and tolerability phase 2 results support advancement to phase 3 in schizophrenia in early 2025 company to host conference call with management at 8 a.m. edt san diego , aug. 28, 2024 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced positive top-line data for its phase 2 clinical study of nbi-1117568 (nbi-'568) in adults with schizophrenia.
NBIX Ratings Summary
NBIX Quant Ranking